Darrell & King LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 46.3% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,477 shares of the company’s stock after acquiring an additional 2,050 shares during the quarter. Darrell & King LLC’s holdings in Eli Lilly and were worth $533,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Hartland & Co. LLC increased its stake in Eli Lilly and by 3.9% in the 2nd quarter. Hartland & Co. LLC now owns 10,787 shares of the company’s stock worth $888,000 after acquiring an additional 401 shares during the last quarter. Highstreet Asset Management Inc. bought a new position in Eli Lilly and in the 2nd quarter worth about $814,000. BARING ASSET MANAGEMENT Ltd bought a new position in Eli Lilly and in the 2nd quarter worth about $1,668,000. Legal & General Group Plc increased its stake in Eli Lilly and by 2.8% in the 2nd quarter. Legal & General Group Plc now owns 5,101,196 shares of the company’s stock worth $419,840,000 after acquiring an additional 136,660 shares during the last quarter. Finally, Alps Advisors Inc. increased its stake in Eli Lilly and by 3.4% in the 2nd quarter. Alps Advisors Inc. now owns 578,098 shares of the company’s stock worth $47,577,000 after acquiring an additional 19,110 shares during the last quarter. Institutional investors and hedge funds own 75.72% of the company’s stock.

LLY has been the topic of a number of research analyst reports. TheStreet upgraded Eli Lilly and from a “c+” rating to a “b+” rating in a research note on Tuesday, July 25th. Berenberg Bank reiterated a “buy” rating and issued a $100.00 price objective on shares of Eli Lilly and in a report on Thursday, July 27th. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective for the company in a report on Monday, July 17th. Deutsche Bank AG reiterated a “buy” rating and issued a $91.00 price objective (up from $90.00) on shares of Eli Lilly and in a report on Monday, July 17th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $96.00 price objective (up from $93.00) on shares of Eli Lilly and in a report on Thursday, July 13th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $88.57.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same quarter in the previous year, the business earned $0.86 earnings per share. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year.

TRADEMARK VIOLATION WARNING: “Eli Lilly and Company (LLY) Shares Bought by Darrell & King LLC” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/10/13/eli-lilly-and-company-lly-shares-bought-by-darrell-king-llc.html.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 180,000 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the completion of the transaction, the insider now owns 123,865,804 shares in the company, valued at $10,040,562,072.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 990,000 shares of company stock valued at $82,949,650 in the last 90 days. Company insiders own 0.20% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.